Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical Co's total inventories for the quarter that ended in Dec. 2025 was NT$12.70 Mil. Acro Biomedical Co's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was NT$12.10 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Acro Biomedical Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$13.46.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Acro Biomedical Co's Days Inventory for the
six
months ended in Dec. 2025 was 217.72.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Acro Biomedical Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.84.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acro Biomedical Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.49.
Acro Biomedical Co (ROCO:6748) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Acro Biomedical Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acro Biomedical Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Acro Biomedical Co Total Inventories Related Terms
Acro Biomedical Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Acro Biomedical Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of NT$12.70 Mil mean?
Acro Biomedical Co (ROCO:6748) has a Total Inventories of NT$12.70 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Acro Biomedical Co and its competitors.
Is Acro Biomedical Co's Total Inventories too high?
Acro Biomedical Co's current Total Inventories is NT$12.70 Mil. Overall, Acro Biomedical Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Total Inventories compare to VRTX and REGN?
Acro Biomedical Co's Total Inventories of NT$12.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Acro Biomedical Co and its competitors. Acro Biomedical Co's current Total Inventories is NT$12.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.13, compared to a current price of NT$295.50 — trading 819.7% above its estimated fair value. The current Total Inventories is NT$12.70 Mil. Acro Biomedical Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Total Inventories is NT$12.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?
Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued.
The current stock price of NT$295.50 is trading 819.7% above its estimated GF Value™ of NT$32.13.
GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.
Key valuation signals for ROCO:6748:
Total Inventories: NT$12.70 Mil
GF Value™: NT$32.13 vs. price of NT$295.50 (819.7% above fair value)
No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
66GF Score
Get the complete analysis for ROCO:6748
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6748 has been successfully added to your 
